About Crinetics
Crinetics is a company based in San Diego (United States) founded in 2008 by Scott Struthers was acquired by Vertex Pharmaceuticals in July 2026. Crinetics has raised $103.5 million across 19 funding rounds from investors including Vertex Pharmaceuticals, NIH and HHS. The company has 437 employees as of December 31, 2024. Crinetics offers products and services including Paltusotine, Atumelnant, and CRN09682. Crinetics operates in a competitive market with competitors including Neurocrine, Zucara Therapeutics, MBX Biosciences, Radionetics and Siolta Therapeutics, among others.
- Headquarter San Diego, United States
- Employees 437 as on 31 Dec, 2024
- Founders Scott Struthers
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Crinetics Pharmaceuticals, Inc.
-
Annual Revenue
$1.04 M (USD)-74.11as on Dec 31, 2024
-
Net Profit
-$298.41 M (USD)-39.1as on Dec 31, 2024
-
EBITDA
-$336.07 M (USD)-51.72as on Dec 31, 2024
-
Total Equity Funding
$103.5 M (USD)
in 19 rounds
-
Latest Funding Round
$350 M (USD), Post-IPO
Mar 01, 2024
-
Investors
Vertex Pharmaceuticals
& 13 more
-
Employee Count
437
as on Dec 31, 2024
-
Acquired by
Vertex Pharmaceuticals
(Jul 06, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Crinetics
Crinetics is a publicly listed company on the NASDAQ with ticker symbol CRNX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Crinetics
Crinetics offers a comprehensive portfolio of products and services, including Paltusotine, Atumelnant, and CRN09682.
Therapy for acromegaly and carcinoid syndrome treatment
Treatment for congenital adrenal hyperplasia
Targets neuroendocrine tumors and SST2-expressing cancers
People of Crinetics
Unlock access to complete
Unlock access to complete
Leadership Team
57 people
Software Development Team
25 people
Senior Team
14 people
Operations Team
10 people
Legal and Compliance
9 people
Product Management Team
9 people
Human Resources and Administration
6 people
Finance and Accounting
6 people
Unlock access to complete
Funding Insights of Crinetics
Crinetics has successfully raised a total of $103.5M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $350 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Crinetics
Crinetics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Vertex Pharmaceuticals, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Crinetics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Crinetics
Investment portfolio details for Crinetics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Crinetics
Detailed financials for Crinetics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Crinetics Comparisons
Peer comparison for Crinetics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Crinetics
Crinetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Zucara Therapeutics, MBX Biosciences, Radionetics and Siolta Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes
|
|
| Locked | Locked | Locked |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| Locked | Locked | Locked |
Peptide-targeted radiopharmaceuticals for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Microbiome therapeutics are provided for treating chronic inflammatory diseases.
|
Detailed competitors of Crinetics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Crinetics
Complete news archive for Crinetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Crinetics
Crinetics was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Crinetics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Scott Struthers is the current CEO of Crinetics. They have also founded this company.
Crinetics is a funded company, having raised a total of $103.5M across 19 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Crinetics is 437.
Annual revenue of Crinetics is $1.04M as on Dec 31, 2024.
Developer of therapies for the treatment of endocrine-related diseases and cancers. The company focuses on the development of drugs for endocrine disorders and cancers in the areas of neuroendocrinology, reproductive medicine, and womens health. Its lead candidate is CRN04777, an oral SST5 agonist for hypoglycemia.
Crinetics's top competitors include Neurocrine, Zucara Therapeutics and MBX Biosciences.
Crinetics offers Paltusotine, Atumelnant, and CRN09682.
Yes, Crinetics is publicly traded on NASDAQ under the ticker symbol CRNX.
Crinetics has 14 investors. Key investors include Vertex Pharmaceuticals, NIH, HHS, Orbimed, and RA Capital.
The ticker symbol of Crinetics is CRNX on NASDAQ.